{"pmid":32357545,"title":"Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.","text":["Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.","New coronavirus (SARS-CoV-2) treatments and vaccines are under development to combat COVID-19. Several approaches are being used by scientists for investigation, including (1) various small molecule approaches targeting RNA polymerase, 3C-like protease, and RNA endonuclease; and (2) exploration of antibodies obtained from convalescent plasma from patients who have recovered from COVID-19. The coronavirus genome is highly prone to mutations that lead to genetic drift and escape from immune recognition; thus, it is imperative that sub-strains with different mutations are also accounted for during vaccine development. As the disease has grown to become a pandemic, B-cell and T-cell epitopes predicted from SARS coronavirus have been reported. Using the epitope information along with variants of the virus, we have found several variants which might cause drifts. Among such variants, 23403A>G variant (p.D614G) in spike protein B-cell epitope is observed frequently in European countries, such as the Netherlands, Switzerland, and France, but seldom observed in China.","Pathogens","Koyama, Takahiko","Weeraratne, Dilhan","Snowdon, Jane L","Parida, Laxmi","32357545"],"abstract":["New coronavirus (SARS-CoV-2) treatments and vaccines are under development to combat COVID-19. Several approaches are being used by scientists for investigation, including (1) various small molecule approaches targeting RNA polymerase, 3C-like protease, and RNA endonuclease; and (2) exploration of antibodies obtained from convalescent plasma from patients who have recovered from COVID-19. The coronavirus genome is highly prone to mutations that lead to genetic drift and escape from immune recognition; thus, it is imperative that sub-strains with different mutations are also accounted for during vaccine development. As the disease has grown to become a pandemic, B-cell and T-cell epitopes predicted from SARS coronavirus have been reported. Using the epitope information along with variants of the virus, we have found several variants which might cause drifts. Among such variants, 23403A>G variant (p.D614G) in spike protein B-cell epitope is observed frequently in European countries, such as the Netherlands, Switzerland, and France, but seldom observed in China."],"journal":"Pathogens","authors":["Koyama, Takahiko","Weeraratne, Dilhan","Snowdon, Jane L","Parida, Laxmi"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32357545","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/pathogens9050324","keywords":["covid-19","sars-cov-2","antibody","convalescent plasma","genomic drift","immune escape","spike protein","vaccine","variant"],"locations":["Netherlands","Switzerland","France","China"],"countries":["China","France","Switzerland","Netherlands"],"countries_codes":["CHN|China","FRA|France","CHE|Switzerland","NLD|Netherlands"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495303811075,"score":9.490897,"similar":[{"pmid":32106567,"pmcid":"PMC7150947","title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.","text":["Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.","The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.","Viruses","Ahmed, Syed Faraz","Quadeer, Ahmed A","McKay, Matthew R","32106567"],"abstract":["The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2."],"journal":"Viruses","authors":["Ahmed, Syed Faraz","Quadeer, Ahmed A","McKay, Matthew R"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32106567","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.3390/v12030254","keywords":["2019 novel coronavirus","2019-ncov","b cell epitopes","covid-19","coronavirus","mers-cov","sars-cov","sars-cov-2","t cell epitopes","vaccine"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490779205633,"score":277.67325},{"pmid":32249956,"title":"Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein.","text":["Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein.","The recent pandemic of COVID-19, caused by SARS-CoV-2, is unarguably the most fearsome compared with the earlier outbreaks caused by other coronaviruses, SARS-CoV and MERS-CoV. Human ACE2 is now established as a receptor for the SARS-CoV-2 spike protein. Where variations in the viral spike protein, in turn, lead to the cross-species transmission of the virus, genetic variations in the host receptor ACE2 may also contribute to the susceptibility and/or resistance against the viral infection. This study aims to explore the binding of the proteins encoded by different human ACE2 allelic variants with SARS-CoV-2 spike protein. Briefly, coding variants of ACE2 corresponding to the reported binding sites for its attachment with coronavirus spike protein were selected and molecular models of these variants were constructed by homology modeling. The models were then superimposed over the native ACE2 and ACE2-spike protein complex, to observe structural changes in the ACE2 variants and their intermolecular interactions with SARS-CoV-2 spike protein, respectively. Despite strong overall structural similarities, the spatial orientation of the key interacting residues varies in the ACE2 variants compared with the wild-type molecule. Most ACE2 variants showed a similar binding affinity for SARS-CoV-2 spike protein as observed in the complex structure of wild-type ACE2 and SARS-CoV-2 spike protein. However, ACE2 alleles, rs73635825 (S19P) and rs143936283 (E329G) showed noticeable variations in their intermolecular interactions with the viral spike protein. In summary, our data provide a structural basis of potential resistance against SARS-CoV-2 infection driven by ACE2 allelic variants.","J Med Virol","Hussain, Mushtaq","Jabeen, Nusrat","Raza, Fozia","Shabbir, Sanya","Baig, Ayesha A","Amanullah, Anusha","Aziz, Basma","32249956"],"abstract":["The recent pandemic of COVID-19, caused by SARS-CoV-2, is unarguably the most fearsome compared with the earlier outbreaks caused by other coronaviruses, SARS-CoV and MERS-CoV. Human ACE2 is now established as a receptor for the SARS-CoV-2 spike protein. Where variations in the viral spike protein, in turn, lead to the cross-species transmission of the virus, genetic variations in the host receptor ACE2 may also contribute to the susceptibility and/or resistance against the viral infection. This study aims to explore the binding of the proteins encoded by different human ACE2 allelic variants with SARS-CoV-2 spike protein. Briefly, coding variants of ACE2 corresponding to the reported binding sites for its attachment with coronavirus spike protein were selected and molecular models of these variants were constructed by homology modeling. The models were then superimposed over the native ACE2 and ACE2-spike protein complex, to observe structural changes in the ACE2 variants and their intermolecular interactions with SARS-CoV-2 spike protein, respectively. Despite strong overall structural similarities, the spatial orientation of the key interacting residues varies in the ACE2 variants compared with the wild-type molecule. Most ACE2 variants showed a similar binding affinity for SARS-CoV-2 spike protein as observed in the complex structure of wild-type ACE2 and SARS-CoV-2 spike protein. However, ACE2 alleles, rs73635825 (S19P) and rs143936283 (E329G) showed noticeable variations in their intermolecular interactions with the viral spike protein. In summary, our data provide a structural basis of potential resistance against SARS-CoV-2 infection driven by ACE2 allelic variants."],"journal":"J Med Virol","authors":["Hussain, Mushtaq","Jabeen, Nusrat","Raza, Fozia","Shabbir, Sanya","Baig, Ayesha A","Amanullah, Anusha","Aziz, Basma"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249956","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25832","keywords":["ace2","covid-19","sars-cov-2","spike protein"],"topics":["Mechanism"],"weight":1,"_version_":1666138491015135232,"score":250.26945},{"pmid":32301390,"title":"Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction.","text":["Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction.","The emergence of SARS-CoV-2 has led to the current global coronavirus pandemic and more than one million infections since December 2019. The exact origin of SARS-CoV-2 remains elusive, but the presence of a distinct motif in the S1/S2 junction region suggests the possible acquisition of cleavage site(s) in the spike protein that promoted cross-species transmission. Through plaque purification of Vero-E6 cultured SARS-CoV-2, we found a series of variants which contain 15-30-bp deletions (Del-mut) or point mutations respectively at the S1/S2 junction. Examination of the original clinical specimen from which the isolate was derived, and 26 additional SARS-CoV-2 positive clinical specimens, failed to detect these variants. Infection of hamsters shows that one of the variants (Del-mut-1) which carries deletion of 10 amino acids (30bp) does not cause the body weight loss or more severe pathological changes in the lungs that is associated with wild type virus infection. We suggest that the unique cleavage motif promoting SARS-CoV-2 infection in humans may be under strong selective pressure, given that replication in permissive Vero-E6 cells leads to the loss of this adaptive function. It would be important to screen the prevalence of these variants in asymptomatic infected cases. The potential of the Del-mut variants as an attenuated vaccine or laboratory tool should be evaluated.","Emerg Microbes Infect","Lau, Siu-Ying","Wang, Pui","Mok, Bobo Wing-Yee","Zhang, Anna Jinxia","Chu, Hin","Lee, Andrew Chak-Yiu","Deng, Shaofeng","Chen, Pin","Chan, Kwok-Hung","Song, Wenjun","Chen, Zhiwei","To, Kelvin Kai-Wang","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","Chen, Honglin","32301390"],"abstract":["The emergence of SARS-CoV-2 has led to the current global coronavirus pandemic and more than one million infections since December 2019. The exact origin of SARS-CoV-2 remains elusive, but the presence of a distinct motif in the S1/S2 junction region suggests the possible acquisition of cleavage site(s) in the spike protein that promoted cross-species transmission. Through plaque purification of Vero-E6 cultured SARS-CoV-2, we found a series of variants which contain 15-30-bp deletions (Del-mut) or point mutations respectively at the S1/S2 junction. Examination of the original clinical specimen from which the isolate was derived, and 26 additional SARS-CoV-2 positive clinical specimens, failed to detect these variants. Infection of hamsters shows that one of the variants (Del-mut-1) which carries deletion of 10 amino acids (30bp) does not cause the body weight loss or more severe pathological changes in the lungs that is associated with wild type virus infection. We suggest that the unique cleavage motif promoting SARS-CoV-2 infection in humans may be under strong selective pressure, given that replication in permissive Vero-E6 cells leads to the loss of this adaptive function. It would be important to screen the prevalence of these variants in asymptomatic infected cases. The potential of the Del-mut variants as an attenuated vaccine or laboratory tool should be evaluated."],"journal":"Emerg Microbes Infect","authors":["Lau, Siu-Ying","Wang, Pui","Mok, Bobo Wing-Yee","Zhang, Anna Jinxia","Chu, Hin","Lee, Andrew Chak-Yiu","Deng, Shaofeng","Chen, Pin","Chan, Kwok-Hung","Song, Wenjun","Chen, Zhiwei","To, Kelvin Kai-Wang","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","Chen, Honglin"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301390","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1080/22221751.2020.1756700","keywords":["covid-19","coronavirus","sars-cov-2","spike s1/s2 mutant","spike mutant"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138494888574976,"score":240.45534},{"pmid":32454128,"pmcid":"PMC7245302","title":"Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics.","text":["Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics.","The emergence and rapid expansion of the coronavirus disease (COVID-19) require the development of effective countermeasures especially a vaccine to provide active acquired immunity against the virus. This study presented a comprehensive vaccinomics approach applied to the complete protein data published so far in the National Center for Biotechnological Information (NCBI) coronavirus data hub. We identified non-structural protein 8 (Nsp8), 3C-like proteinase, and spike glycoprotein as potential targets for immune responses to COVID-19. Epitopes prediction illustrated both B-cell and T-cell epitopes associated with the mentioned proteins. The shared B and T-cell epitopes: DRDAAMQRK and QARSEDKRA of Nsp8, EDMLNPNYEDL and EFTPFDVVR of 3C-like proteinase, and VNNSYECDIPI of the spike glycoprotein are regions of high potential interest and have a high likelihood of being recognized by the human immune system. The vaccine construct of the epitopes shows stimulation of robust primary immune responses and high level of interferon gamma. Also, the construct has the best conformation with respect to the tested innate immune receptors involving vigorous molecular mechanics and solvation energy. Designing of vaccination strategies that target immune response focusing on these conserved epitopes could generate immunity that not only provide cross protection across Betacoronaviruses but additionally resistant to virus evolution.","Eur J Pharm Sci","Ahmad, Sajjad","Navid, Afifa","Farid, Rabia","Abbas, Ghulam","Ahmad, Faisal","Zaman, Naila","Parvaiz, Nousheen","Azam, Syed Sikander","32454128"],"abstract":["The emergence and rapid expansion of the coronavirus disease (COVID-19) require the development of effective countermeasures especially a vaccine to provide active acquired immunity against the virus. This study presented a comprehensive vaccinomics approach applied to the complete protein data published so far in the National Center for Biotechnological Information (NCBI) coronavirus data hub. We identified non-structural protein 8 (Nsp8), 3C-like proteinase, and spike glycoprotein as potential targets for immune responses to COVID-19. Epitopes prediction illustrated both B-cell and T-cell epitopes associated with the mentioned proteins. The shared B and T-cell epitopes: DRDAAMQRK and QARSEDKRA of Nsp8, EDMLNPNYEDL and EFTPFDVVR of 3C-like proteinase, and VNNSYECDIPI of the spike glycoprotein are regions of high potential interest and have a high likelihood of being recognized by the human immune system. The vaccine construct of the epitopes shows stimulation of robust primary immune responses and high level of interferon gamma. Also, the construct has the best conformation with respect to the tested innate immune receptors involving vigorous molecular mechanics and solvation energy. Designing of vaccination strategies that target immune response focusing on these conserved epitopes could generate immunity that not only provide cross protection across Betacoronaviruses but additionally resistant to virus evolution."],"journal":"Eur J Pharm Sci","authors":["Ahmad, Sajjad","Navid, Afifa","Farid, Rabia","Abbas, Ghulam","Ahmad, Faisal","Zaman, Naila","Parvaiz, Nousheen","Azam, Syed Sikander"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454128","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ejps.2020.105387","keywords":["3c-like proteinase","coronavirus disease (covid-19)","non-structural protein 8","spike glycoprotein","vaccinomics"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1667983494574243841,"score":235.96484},{"pmid":32473352,"title":"Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","text":["Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs.","Infect Genet Evol","Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin","32473352"],"abstract":["The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs."],"journal":"Infect Genet Evol","authors":["Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473352","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.meegid.2020.104382","keywords":["diagnostics","epitopes","sars-cov-2","spike protein"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193388548096,"score":222.85248}]}